

Mardi 04 avril 2017

Matin :

- Accueil des étudiants de 8h30 à 9h00
- 9h00 / 11h00
 - Spondylodiscites chez l'adulte
 - Pr François PROUST – CHRU de Strasbourg
- 11h15 / 13h00
 - Ostéomyélites chez l'enfant
 - Pr Pierre JOURNEAU – CHRU de Nancy
 - Ostéomyélite chez l'adulte
 - Pr Didier MAINARD – CHRU de Nancy

Centre de Référence pour la prise en charge des Infections **Ostéo-Articulaires Complexes**
Centre Chirurgical Emile Gallé – 49 rue Hermite – Bâtiment B – 3^{ème} étage – CS 75211 – 54052 NANCY CEDEX
Téléphone : 33 (0)3 83 85 75 61 – Télécopie : 33 (0)3 83 85 78 22
M@il : crioacgrandest@chru-nancy.fr
Site Web : www.crioacgrandest.fr


LM/21/12/2016

- **> 50 ans**
- **Lombaire**
- **Génito-urinaire**
- **Retard diagnostique 3 mois**
- **WBC normal**
- **Fièvre**

Ostéomyélite ?

**Risque
Neurologique ?**

Discite?



Epidémiologie

- **2-7% infections ostéo-articulaires**
- **Incidence: 1/100 000 – 250 000**
- **Pics : < 20 et 50-70**
- **F/M ratio: 2/1-5/1**

Facteurs de risque

- **Chirurgie rachis**
- **Diabète**
- **IV**
- **HIV**
- **Oncologie**
- **Néphropathie**
- **Rhumatologie**
- **Cirrhose**

Epidémiologie:

Spondylodiscite à pyogènes:

Lombaire **60 %**

Dorsale **30 %**


Cervicale **10 %**

Bifocale **10 %**

BK:



plus fréquent au rachis dorsal


bi ou plurifocale > 20 %



Etiologie

- **Pyogènes**
 - **Staphylococcus aureus : 30-80%**
 - **BGN, Escherichia coli : 25%**
 - **Streptococcus,**
 - **Poly microbien (5%)**
- **Mycobacterium tuberculosis**
 - **60% (Immunodép.)**
- **Anaérobie (plaie pénétrante)**
- **Brucellose (Europe est, méditerranée)**





HEMATOGENE

EXTENSION


Os

Para spinale

Canal rachidien

Cas particulier pédiatrie

- **Cervical (11%)**
- **Dorsal (30%)**
- **Lombaire (58%)**



Clinique

- **Symptômes**

- Rachialgies, (15% sans), tenace, nocturne
- Radiculagies ?
- Fièvre (1/2)

- **Examen**

- Déformations; raideurs; tuméfactions
- Cardiopathie...
- Membres inférieurs, troubles sphinctériens, ...

Biologie

- VS: sensibilité (+), spécificité ???
- CRP: sensibilité > 90%, marqueurs évolutifs
- Comptage des PNs ?
- Cultures : sang, urines !!!! (59%)
 - Aérobie et anaérobie !!!!!!!

TABLE 1: Characteristics of our study population*

Characteristic	Value (%)
no. of patients	102
sex	
male	88 (86.3)
female	14 (13.7)
age (yrs)	
mean	45.4
range	22–66
WBC count at presentation	
mean ($\times 10^3$ cells/ μ l)	11.1
range ($\times 10^3$ cells/ μ l)	0.5–32
no. of pts w/ abnormal WBC count	50 (49)
ESR at presentation	
mean (mm/hr)	74
range (mm/hr)	9.9–140
no. of pts w/ abnormal ESR	93 (91)
CRP level at presentation	
mean (mg/L)	67
range (mg/L)	0.1–323
no. of pts w/ abnormal CRP level	73 (71.6)

Neurosurg Focus 37 (2):E3, 2014
©AANS, 2014

and management of primary pyogenic spinal infection in intravenous recreational drug users




J.D.,^{1,2} BRADLEY DENGLER, M.D.,² DAVIN CORDELL, M.D.,² MARTANUSZ, M.D., Ph.D.²

Spine Institute, Austin; and ²Department of Neurosurgery, University of Texas Health Science Center at San Antonio, Texas

Primary spine infection secondary to intravenous drug abuse (IVDA) is a difficult clinical entity encountered by neurosurgeons and infectious disease specialists. Patients tend to be noncompliant with the treatment and often continue to use IV recreational drugs even after the diagnosis of spine infection. The authors sought to analyze the presentation, etiology, demographic characteristics, treatment, and outcome of primary spine infection in patients with IVDA as the major risk factor.

The medical records, radiology imaging, and laboratory results (white blood cell count, inflammatory markers, and microbiology cultures) of all patients with pyogenic spine infection and history of IVDA presenting to the University of Texas Health Science Center at San Antonio from August 2005 through December 2013 were retrospectively reviewed. The department of neurosurgery and the hospital electronic medical records of University Hospital in San Antonio were used for our study.

A total of 164 patients with spinal infection were evaluated during the study period; 102 of these patients had IVDA. Their average age was 45.4 years, and only 14 (13.7%) were women. The mean laboratory findings included a white blood cell count of 11.1×10^3 cells/ μ l (range 0.5–32 $\times 10^3$ cells/ μ l), erythrocyte sedimentation rate (ESR) of 74 mm/hr (range 9.9–140 mm/hr), and C-reactive protein (CRP) level of 67 mg/L (range 0.1–323 mg/L). Twenty-six patients (25.4%) had an associated epidural abscess. The most common organism isolated from the bone and/or blood was methicillin-sensitive *Staphylococcus aureus* (MSSA), which was found in 23 cases. A close second was methicillin-resistant *S. aureus* (MRSA), found in 23 cases. The most common region was the lumbar spine (24 cases [57.8%]), and most patients (69.6%) had involvement of the vertebral body.



Computed tomography–guided percutaneous biopsy for vertebral osteomyelitis: a department’s experience

TABLE 1: Yield of histology and microbiology per total number of cases collected when there was clinical suspicion of vertebral osteomyelitis

Results	No. of Samples	
	Histology	Microbiology
positive	26	16
negative	42	68
total	68	84

Neurosurg Focus / Volume 37 / August 2014

**KOSMAS, M.D., PETER C. YOUNG, M.D.,
, AND MARK R. ROBBIN, M.D.**

Hospital Case Medical Center, Cleveland, Ohio

has been reported to occur in approximately 0.2–2 cases per 100,000 annually. Erythrocyte sedimentation rate and C-reactive protein suggest inflammatory etiology. From radiography and CT scanning to nuclear medicine imaging and contrast-enhanced MRI for osteomyelitis. Although MRI has a strong sensitivity and specificity for osteomyelitis, histological and microbiological samples remain the gold standard in diagnosis. A specific pathogen cultured, thereby preventing the need for surgical intervention. In reports that have questioned the percentage yield of image-guided percutaneous biopsies for vertebral osteomyelitis.

After institutional review board approval, the authors performed a chart review of patients who had undergone image-guided percutaneous bone biopsies at University Hospitals Case Medical Center in Cleveland, Ohio. Data were filtered for patients in whom a biopsy sample of a vertebral body/disc was obtained. A total of 213 procedures were performed, of which clinicians indicated a concern for infection in 84, infection or neoplasm in 13, and a noninfectious etiology (the majority being neoplasms) in the remaining 116.

Results. Histological examination provided positive results in 25 (41.0%) of the 61 samples collected for suspected cases of osteomyelitis. Microbiology samples were less predictive, with only 16 of the 84 samples collected, or 19.0%, yielding a positive result. In 10 patients there were positive blood and/or urine cultures. Of these, 8 samples (80%) demonstrated the same pathogen identified by biopsy (for the remaining 2 positive systemic cultures, no pathogen was identified by the percutaneous intervention). In other words, half of the 16 cases that provided microbiological results from biopsy demonstrated the same results by systemic cultures. However, 89 (76.7%) of the 116 samples collected with the primary concern of neoplasm yielded results.

Conclusions. Image-guided percutaneous biopsy for vertebral osteomyelitis demonstrates an extremely low probability of identifying specific microbes. Blood or urine cultures concurrently identified culprit pathogens in 50% of positive biopsy cultures. Therefore, in only 8 (9.5%) of 84 biopsies did the biopsy results provide additional information to clinicians as to the pathological microorganism present and how treatment might need to be adjusted. (<http://thejns.org/doi/abs/10.3171/2014.6.FOCUS14134>)

KEY WORDS • CT-guided biopsy • vertebral osteomyelitis • spondylitis


- **Gram smear**
- **Aerobic**
- **Anaerobic**
- **Fungal**
- **Tuberculosis**
- **Interferon-gamma release assays (IGRA)**

Imagerie

- **Radiographie**
 - Plateaux vertébraux
 - Pincement discal
 - Déformation sagittal



- **Tomodensitométrie**
 - **Plateaux vertébraux**
 - **Nécrose osseuse**
 - **Calcifications**
 - **Biospie ?**











- **IRM**
 - **T1: hyposignal (disque et corps V.)**
 - **T2: hypersignal (œdème)**
 - **Gado: rehaussement**
 - **Disque**
 - **Corps**
 - **Structures environnantes**
 - **Tuberculose**
 - **Abcès parties molles**
 - **Pas le disque**
 - **Rehaussement hétérogène**





















Table 1 Imaging features that can strongly support differential diagnosis of spinal infection etiologies [23, 61, 68–70]

	Pyogenic	Tuberculous	Brucellar	Fungal
Spine segment	Lumbar	Thoracic/thoracolumbar junction	Lower lumbar	Lumbar
Vertebral body (VB)	Early stage: anterior aspect of VB classically VB T1 hypo- and endplate T2 hyperintensity Late stage: VB destruction; T2 hyperintensity and homogeneous enhancement; Adjacent VB involvement	Early stage: anterior aspect of VB three patterns: para discal (more common)—discal involvement and contiguous spread to adjacent VB, T1 hypointensity and T2 heterogenous hyperintensity. Anterior— anterior scalloping of VB and large subligamentous abscesses Central— vertebra plana deformity; IVD not involved Late stage: T1 variable intensity with bone healing	Relatively preserved VB	Involvement: serrated margins of vertebral endplates without severe VB destruction
Disc space involvement	Present: early stage involvement T2 hyperintensity and enhancement	Variable: from disc space sparing up to severe destruction	Present	Typically spared; lack of T2 hyperintensity
Paraspinal/epidural space involvement	If present: inflammation and/or small abscesses with thick and irregular rim enhancement	Present: large paraspinal abscesses; thin and smooth rim enhancement	Typically not present: lack of paraspinal abscess	Present: Small paraspinal abscesses thick and irregular rim enhancement
Posterior elements	Typically not involved	Can be involved	Typically not involved	Can be involved Rib heads also
Anterior subligamentous spread	Uncommon	Present: can be more extensive than the vertebral involvement	Uncommon	Common
Adjacent vertebral levels involvement	Present: endplate destruction	Present: high bone destruction	Uncommon	Uncommon
Multilevel involvement	Uncommon	Common: skip lesions	Uncommon	Common: skip lesions


Traitement




- **Antibiothérapie**
- **Immobilisation du segment infecté**
- **Restauration équilibre sagittal**
- **Débridement abcès épidural, ou compression neurologique**

- **Aureus ou coli**
- **SMRA: vancomycin**
- **Tuberculosis:**
 - **Isoniazide**
 - **Rifampicin,**
 - **Pyrazinamide**
 - **Ethambutol**
- **Fungal : antimycotique**










- **Conservative**
 - **Minime déformation**
 - **Immobilisation : orthèse**
 - **Décubitus**



- **Surveillance**
 - **Biologie**
 - **Imagerie (CT scan / IRM)**
 - **Ponction sous CT scan (psoas)**

Table 1 Indications for surgery in spondylodiscitis

Indications for surgery in spondylodiscitis

1. Neurological deficits
 2. Sepsis
 3. Significant bone involvement with instability
 4. Impending or current deformities
 5. Intraspinous space-occupying processes (i.e. spinal abscess)
 6. Unclear aetiology of the process and/or suspected malignant disease
 7. Failure to respond to conservative therapy
 8. Uncontrollable pain
 9. Patient's lack of compliance
-

Indication chirurgicale ?

- **Objectifs**
 - Débridement
 - Prélèvements
- **Urgence**
 - Compression neurologique
 - Processus infectieux évolutif
- **Différée**
 - Déformation
 - Fixation - stabilisation ?

Compression : abcès épidural

- **50% hémotogène**
- **38% direct extension**
- **Thrombophlébite septique**
- **Laminectomie, lavage, drain épidural**




FIG. 1. Evidence-based algorithm for triaging patients with SEA to operative treatment combined with antibiotics versus non-operative treatment with antibiotics alone. Units of measure used for CRP were mg/L, and for WBC count the units were $\times 10^9$ cells/L.




TABLE 1: Clinical cohorts reporting the treatment and outcome for SEA in more than 50 patients*

Authors & Year	Description of Study	Evidence Class	Conclusions
Rigamonti et al., 1999	retrospective cohort of 75 cases w/ SEA	III	surgical drainage & prolonged antibiotics are the first-line treatment for SEA, but select pts can be treated conservatively
Siddiq et al., 2004	retrospective analysis of 57 pts w/ 60 cases of SEA (28 were treated surgically, 25 medically, & 7 w/ percutaneous needle drainage)	III	SEA can be safely & effectively managed w/ prolonged IV antibiotics alone or combined w/ CT-guided percutaneous needle drainage, irrespective of age, presence of comorbid illness, disease onset, neurological deficits at presentation, or abscess size
Davis et al., 2004	retrospective cohort of 63 pts w/ SEA	III	diagnostic delay in 75% of SEA pts; those w/ diagnostic delays were more likely to have residual motor weakness
Savage et al., 2005	retrospective review of 52 pts w/ SEA; 29 pts were treated w/ initial nonop management	III	11% failure rate of nonop management; medical management w/ close clinical follow-up is safe in select pts w/ SEA
Karikari et al., 2009	retrospective cohort of 104 cases of SEA (64 pts treated conservatively; pts w/ lumbar disease & no neurological deficit were more often treated conservatively)	III	in select pts conservative therapy is an option; ventral SEA may be more amenable to conservative management (pts treated w/ surgery were more likely to have an improvement in neurological examination findings)
Davis et al., 2011	retrospective/prospective cohort of 86 pts comparing management of SEA before (55) & after (31) implementation of diagnostic guideline	III	implementation of the guideline involving risk factor assessment followed by ESR & CRP testing led to a decrease in diagnostic delay & motor deficits
Kim et al., 2013	retrospective cohort of 355 cases of SEA; of 127 pts initially treated nonoperatively, medical management failed in 54	III	age >65 yrs, diabetes, MRSA, & neurological impairment involving the spinal cord all independently predict failure of medical management for SEA
Connor et al., 2013	retrospective cohort of 77 pts treated for SEA; 57 cases were treated surgically	III	age & preop weakness are correlated w/ outcome; decompressive surgery significantly improves outcome in pts w/ focal weakness
Patel et al., 2014	retrospective cohort of 128 cases of SEA comparing initial surgical (77) & medical (51) management	III	early surgery is superior to surgical treatment delayed by a trial of medical management (diabetes, CRP > 115 mg/L, WBC count > 12.5×10^9 cells/L, & bacteremia predict failure of medical management)
Adogwa et al., 2014	retrospective cohort of 82 pts w/ SEA who were >50 yrs of age	III	early surgical decompression combined w/ IV antimicrobial therapy was not associated w/ superior clinical outcomes when compared w/ IV antimicrobial therapy alone, although the surgery group had a significantly higher rate of pt improvement

* ESR = erythrocyte sedimentation rate; IV = intravenous; pt = patient.

Medical and surgical management of spinal epidural abscess: a systematic review

LEOPOLD ARKO IV, M.D.,¹ ERIC QUACH, B.S.,² VINCENT NGUYEN, B.S.,² DANIEL CHANG, A.B.,² VISHAD SUKUL, M.D.,¹ AND BONG-SOO KIM, M.D.¹

¹Department of Neurosurgery, ²Temple University School of Medicine, Philadelphia, Pennsylvania




FIG. 2. Comparison between patients undergoing surgical and medical management for treatment of SEA with historical control. Bar graph representing distribution of surgical to nonsurgical forms of treatment from current (pooled) data versus historical control. There was a significant difference in the proportions of treatment method implemented in the current studies over the historical control ($p < 0.01$).




FIG. 3. Comparison of surgical and medical management given presenting deficits in patients with SEA. Group 1 included patients presenting without neurological deficit, with or without back pain. Group 2 included those presenting with neurological deficits, with or without back pain. The correlation between presenting deficits and management method was highly significant (Fisher's exact test, $p < 0.01$).

urgent surgical
for the nonop-
managed SEA
published. This

epidural ab-
1 publications
published that
the references
8 years) were
orting indica-
xcluded.

tained. These
5% of treated
occus aureus
medical therapy
nparison with
more likely to
etween surgi-
nent.

l trend toward
a fair number

of cases involving patients with specific risk factors, and patients with these risk factors should be closely observed in consideration for surgery. Further research may help identify patients at greater risk for failure of medical therapy. (<http://thejns.org/doi/abs/10.3171/2014.6.FOCUS14127>)

KEY WORDS • conservative management • central nervous system infection • surgical decompression • spinal osteomyelitis • spinal epidural abscess • spinal infection

Ostéosynthèse dans tuberculose ?

- **1950**
- **Débridement**
- **Fusion autogreffe**
- **Immobilisation**
- **Fusion : 90%**

Stabilisation – fixation postérieure ?

Parameter	Value†
mean age in yrs	59 ± 10.4
sex distribution	80% M, 20% F
mean Charlson Comorbidity Index	2
mean ASA score	2.8
prior spine surgery	60%
mean BMI	29.5 ± 8.1
average preop albumin in g/dl	2.1
preop neurological deficit	12 (80)
bony instability	13 (86)
failure of prior treatment	8 (53)




TABLE 3: Details of infectious organism, antibiotic therapy, nutritional status, and neurological outcome*

Case No.	Organism	Follow-Up Length (mos)	IV Antibiotic Duration	Oral Antibiotic Duration	Initial Serum Albumin (g/dl)	Frankel Grade		Final Ambulatory Status
						Preop	Postop	
1	MRSA	65	6 wks nafcillin	unclear†	2.6	E	E	ambulatory
2	coagulase-negative <i>Staphylococcus</i> spp.	24	12 wks vancomycin	lifetime suppression	1.5	C	D	ambulatory w/ assistive device
3	MRSA	42	6 wks vancomycin	lifetime suppression	2.2	B	E	ambulatory
4	MSSA	56	unclear†	unclear†	1.4	A	D	ambulatory w/ assistive device
5	MSSA	54	unclear†	unclear†	2.0	B	D	ambulatory w/ assistive device
6	MRSA	60	8 wks vancomycin	lifetime suppression	1.6	B	D	ambulatory
7	MSSA	36	12 wks cefazolin	8 mos	3.0	C	D	ambulatory
8	MSSA	14	12 wks nafcillin & rifampin	lifetime suppression	1.6	B	A	nonambulatory
9	MSSA	15	12 wks nafcillin	lifetime suppression	1.4	B	D	ambulatory w/ assistive device
10	MRSA	36	6 wks vancomycin & linezolid	lifetime suppression	3.0	E	E	ambulatory
11	<i>Ralstonia pickettii</i>	29	6 wks ceftriaxone & clindamycin	4 mos	2.7	D	E	ambulatory
12	culture negative 1	20	8 wks ceftriaxone	lifetime suppression	1.6	D	D	ambulatory w/ assistive device
13	MSSA	0	lost to follow-up	lost to follow-up	2.1	D	D	lost to follow-up
14	group A <i>Streptococcus</i>	12	6 wks ceftriaxone	lifetime suppression	1.9	C	D	ambulatory w/ assistive device
15	culture negative	12	6 wks daptomycin & Zosyn	lifetime suppression	3.4	E	E	ambulatory

1) GENERAL INFORMATION

Titre du projet (français) : Comparaison de l'immobilisation par corset ou ostéosynthèse percutanée dans la spondylodiscite bactérienne de l'adulte en complément du traitement antibiotique

Acronym :

Brace versus percutaneous instrumentation in spondylodiscitis

Project title (anglais) : Comparison of brace treatment versus percutaneous instrumentation in adult pyogenic spondylodiscitis combined with antibiotic treatment

First submission to DGOS calls for proposals ?

Tick : ☒ Yes ☐ No

If "No", mention the year of previous submission :

First name and name of the coordinator :

Pr Yann Philippe CHARLES, Service de Chirurgie du Rachis, Hôpitaux Universitaires de Strasbourg, 1 Place de l'hôpital, B.P. 426, 67091 Strasbourg Cedex, Tél. 0388116826, Email : yann.philippe.charles@chru-strasbourg.fr

Speciality : Orthopaedic surgery

Pr Jacques-Eric Gottenberg, Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, 1 Place de l'hôpital, B.P. 426, 67091 Strasbourg Cedex, Tél. 0388128189, Email : jacques-eric.gottenberg@chru-strasbourg.fr

Speciality : Rheumatology

Table 3

Patient Demographics and Preoperative/Postoperative Visual analogue scale (VAS) scores

Patient	Neurologic deficit	Symptoms	Preoperative VAS pain	Postoperative VAS	Discharge VAS	Follow-up VAS
1	No	Back pain	7	3	3	4
2	No	Back pain	8	0	0	0
3	No	Back pain	10	8	6	0
4	No	Back pain, bilateral leg pain	10	7	5	N/A
5	No	Back and leg pain	8	6	6	0
6	No	Back pain	9	6	6	2
7	Yes	Back and bilateral leg pain, foot drop	10	8	5	0

VAS - Visual Analog Scale




Fig. 1 *Escherichia coli* infectious spondylodiscitis of L3-4 in a patient with a past history of colon cancer (**a**). Disc space was narrowing with nearby destructed endplates on L3-4 level; **b** Osteomyelitis in L3-4 vertebral bodies, discitis and psoas abscess without epidural abscess were found in gadolinium-enhanced magnetic resonance imaging; **c** Anterior and posterior spinal surgery was noticed in the immediate postoperative X-ray; **d** and **e** Solid bone fusion was noticed at the 2-year follow-up